Home/AI/@metanova_labs
63
Score · promising
Scored 2mo ago · may be stale

@metanova_labs

METANOVA LABS

Metanova Labs is an early-stage decentralized AI drug discovery platform built on Bittensor (Subnet 68). They run continuous competitions for small molecule screening, nanobody design, and chemical search algorithms with daily rewards totaling ~$10k. The project has begun experimental validation partnerships (Yalotein for nanobody production) and maintains active technical development with regular algorithm improvements. Account is ~9 months old with <5k followers, positioning it as genuinely early-stage despite substantive technical activity.

AI Analysispromising

Confidence
78%

Metanova Labs is an early-stage decentralized AI drug discovery platform built on Bittensor (Subnet 68).

They run continuous competitions for small molecule screening, nanobody design, and chemical search algorithms with daily rewards totaling ~$10k.

The project has begun experimental validation partnerships (Yalotein for nanobody production) and maintains active technical development with regular algorithm improvements.

Account is ~9 months old with <5k followers, positioning it as genuinely early-stage despite substantive technical activity.

Green flags: Real technical execution: regular subnet updates, filter improvements (BRENK), parallelization optimizations (20x molecule evaluations) · Experimental validation underway via partnership with Yalotein for nanobody production · Built on established infra (Bittensor Subnet 68) with transparent competition mechanics and daily rewards · Early-stage metrics: 4.5k followers, account created Nov 2024, not yet widely known outside Bittensor ecosystem · Credible team signal: CSO presenting at conferences, whitepaper available, professional website redesign

Red flags: Drug discovery is extremely long-horizon with uncertain commercial outcomes · Token utility and value capture mechanism not clearly explained in available data · Relatively low engagement (avg 120) given follower count suggests limited organic traction so far

Token
$NOVA · announced
Chain
Bittensor
Stage
mainnet+live
Category
DeSci drug discovery

Recent tweetsSee all on 𝕏 →

Huge thanks to @Ginkgo for giving @metanova_labs co-founders @pennapdr, @42salamandas, and @urdof07 a tour of their incredible robotics lab in Boston! The scale of automation and experimental throughput they've achieved is remarkable. The future of lab-in-the-loop discovery is here.
1w ago♥ 79💬 4🔁 13
Watch full episode @micaelabazo (Co-founder & CEO) and @pennapdr (Co-founder & CSO) of @metanova_labs sit down with @KhalaResearch @haitzu and @Lemz0x to discuss - NOVA’s first lab results - Competition participants behind NOVA - How new drugs actually reach the market - Why AI labs are moving into pharma - Where value accrues https://t.co/Bz9hEMYIxm
1w ago♥ 60💬 2🔁 12
NOVA: Emission Split Update for Data Generation Fund Owner 26% / Miners 33% / Validators 41% With the launch of eTAO, subnet owners can now adjust how emissions are distributed. NOVA will be updating its split to allocate more resources toward what we believe is the highest-impact investment we can make in the subnet's future: experimental data generation. Wet lab data is the best investment we can make both to prove out what the subnet produces and to increase the value of what gets built on top of it. Data is the bottleneck AI-driven drug discovery faces a fundamental constraint: the quality of our predictions is ultimately limited by the experimental data available to train and validate them. Much of today's publicly available drug discovery data is fragmented across studies, generated using different experimental protocols, and inconsistent in quality and coverage. Generating high-quality experimental data allows us to address that limitation directly. It gives miners better ground truth for model development, provides independent validation of their predictions, and helps us identify which approaches actually translate into experimental success. The industry is making the same bet. Some of the largest investments in AI-driven biology are now directed toward generating the experimental data necessary to train and validate better models. Biohub committed $400M of a $500M, five-year initiative to data generation, infrastructure and measurement technology, and later expanded into a $1.8B effort backed by Meta, Google DeepMind and Isomorphic Labs, who collectively committed $300M. The OpenAI Foundation gave $15M to OpenADMET to generate public ADME datasets, which will be used in prospective blind challenges against newly measured experimental data. Octant continues the high-throughput data generation behind it. Leash Bio used a $9.3M seed round to scale data collection for a foundational medicinal chemistry model, producing a dataset that screened 133 million molecules against each protein. Anthropic has set up a physical biology lab in the Bay Area. What the additional funds will support The additional owner allocation will go into a dedicated R&D fund for wet lab data generation. 1. ADME model training competition. The first use of the fund is generating the experimental data behind our ADME competition, currently in design and development. High-quality, standardized ADME data is what turns a competition from a benchmark into something that produces models with real predictive value. 2. Advancing assets under development. Where it makes sense, the fund can also support experimental work that moves our in-development assets forward. Why this benefits the entire NOVA ecosystem We believe generating experimental data is one of the most effective ways to increase the long-term value of the subnet. For miners, better datasets and scientifically grounded evaluations create opportunities to develop more capable models, compete on meaningful performance improvements, and contribute work with greater real-world utility. For validators, stronger experimental benchmarks improve the ability to assess model quality and reward useful contributions. For tokenholders, better models, experimentally validated discoveries, and progress toward valuable therapeutic assets can strengthen NOVA's competitive position and long-term commercial potential. The economic opportunity extends beyond any individual competition. We are building an increasingly capable scientific discovery platform, and the data generated through our R&D efforts can become a compounding asset for the entire ecosystem. Miner incentives remain strong Miners will still receive a meaningfully larger share than the owner (33% vs. 26%), and we believe the rewards will preserve healthy, competitive incentives for participation. Better data and better-validated competitions also make the work miners do more valuable over time. Protecting token health Funds from the R&D allocation will be converted to cover lab costs gradually, distributed over time rather than sold in size, to limit market impact and preserve token health. The bottom line We think this is the single best thing we can do to accelerate our progress, increase our chance of success, and create value for everyone with a stake in NOVA, including miners, validators, and tokenholders. It is time for us to scale real-world validation.
2w ago♥ 46💬 3🔁 8
Why are @AnthropicAI, @OpenAI, and @Google accelerating investment in AI drug discovery? Is it: Technical ambition? Drug discovery is one of the hardest real-world problems and a real stress test for AI capabilities. Economic incentives? Capturing a share of pharma’s enormous upside could help justify the massive cost of developing frontier AI and provide a path to profitability. Public perception? Medical innovation is one of AI’s most noble applications and could help shift sentiment at a time when many are concerned about its negative impact on society. @pennapdr and @micaelabazo speculate on what’s driving this growing interest in conversation with @haitzu.
2w ago♥ 24💬 1🔁 3
NOVA Hit-to-Lead Optimization Agent In collaboration with @chutes_ai and @onepot_ai We're developing a Hit-to-Lead optimization agent that integrates an algorithm developed by a NOVA Blueprint winner, extending NOVA's capabilities beyond hit discovery and into the iterative optimization of small molecules. The system combines a domain-specialized AI agent with proprietary combinatorial chemical databases supplied by our partner Onepot AI, spanning billions of possible compounds, that are delivered within 5-7 business days. Researchers will be able to guide the agent in developing, comparing and refining optimization strategies, exploring chemical modifications and prioritizing candidates based on predicted affinity, selectivity, physicochemical properties and specific binding interactions. Confidentiality is a central design requirement. Pharmaceutical R&D involves valuable intellectual property, including compound structures, targets, emerging chemical series and optimization strategies that cannot be exposed publicly. The Chutes team integrated domain specific models so that we can run inference in their verified Trusted Execution Environments (TEEs), with encrypted communication and controlled access to proprietary databases and project records. This architecture is intended to support confidential inference on external infrastructure while preserving organizational control over sensitive research data. Finding a molecule with promising predicted affinity is only the beginning. Hit-to-Lead optimization involves balancing multiple, often competing objectives, including potency, selectivity, physicochemical properties and synthesizability, before progressing toward experimental activity and ADME validation. The next step is to integrate the agent into our own Hit-to-Lead development program. For NOVA, this represents an important step toward translating algorithms developed through open competition into tools for proprietary drug discovery programs, including our own asset-development pipeline and those of external research partners.
2w ago♥ 67💬 4🔁 15

Signal Timeline

0X
@0xKant_ followed
BFirst discovered·2mo ago

Score breakdown0–100

🎯Scout conviction
+18.2 / 35
📚Scout consensus
0 / 10
🪪Profile & earliness
+14 / 20
✍️Substance
+15 / 20
🤖AI verdict
+21.9 / 30
⚠️Penalties
-6 / 40
63
Below threshold (74)
Watching for additional signals.
Followers
4.5K
Account age
1.9y
Scouts
1
First seen
2mo ago